DAX-044 in Adults With Advanced Solid Tumours: a First-in-human Study of Safety, Dose and Early Anti-cancer Activity.
A Phase 1 First-in-human Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumour Activity of Intravenous DAX-044 in Adults With Advanced Solid Tumours.
This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety and tolerability of DAX-044 as monotherapy, and to determine its maximum tolerated dose, in adults with advanced solid tumours.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and anti-tumour activity of DAX-044, a targeted, potency-optimised interleukin-12 (IL-12) immunocytokine, as monotherapy in adults with advanced solid tumours.
Part 1 (dose escalation) will evaluate DAX-044 monotherapy across planned dose levels, using a Bayesian optimal interval (BOIN) design to determine the maximum tolerated dose (MTD). Participants with any of the eligible tumour types are enrolled together into dose-level cohorts. Each participant remains at their allocated dose level; escalation occurs between cohorts only. Additional participants may be enrolled into backfill cohorts at dose levels already cleared for safety.
Part 2 (dose expansion) will further evaluate the safety and anti-tumour activity of DAX-044 monotherapy, at dose levels selected from Part 1, in up to 4 tumour-specific expansion cohorts.
In both parts, DAX-044 is given by intravenous infusion on Day 1 of each 21-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent or sponsor termination, to a maximum of 24 months.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Iva Nikolic
- 전화번호: +61 3 9067 5625
- 이메일: clinops@audax.bio
연구 연락처 백업
- 이름: Joanne Yan
- 전화번호: +61 3 9067 5625
- 이메일: clinops@audax.bio
연구 장소
-
-
Western Australia
-
Nedlands, Western Australia, 호주, 6009
- Linear Clinical Research Ltd
-
연락하다:
- Desi du Plessis
- 전화번호: +61 8 63825100
- 이메일: actcstartup@linear.org.au
-
수석 연구원:
- Timothy Guy Humphries
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Aged at least 18 years.
- Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer, gastric or gastro-oesophageal junction adenocarcinoma, squamous cell carcinoma of the head and neck, melanoma other than ocular or uveal, triple-negative breast cancer, castrate-resistant prostate cancer (CRPC), microsatellite stable colorectal cancer, pancreatic ductal adenocarcinoma, or epithelial ovarian cancer. Tumour-type-specific requirements for prior therapy also apply.
- Measurable disease by RECIST v 1.1, except CRPC, which may be measurable or non-measurable.
- At least 1 prior line of systemic standard-of-care therapy, with radiographic progression on or after the last line received. CRPC with non-measurable disease must instead show progression of PSA.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy greater than 3 months.
- Able to provide pre-treatment tumour tissue, either archival or as a fresh biopsy.
- Adequate organ function within 14 days before first dose, including absolute neutrophil count greater than or equal to 1.5 x 10^9/L, platelets greater than or equal to 100 x 10^9/L, haemoglobin greater than or equal to 9 g/dL, bilirubin less than or equal to 1.5 times the upper limit of normal (ULN), transaminases less than or equal to 3 times the ULN (5 times the ULN if liver metastases are present), and creatinine clearance greater than or equal to 50 mL/min.
- Agreement to use contraception according to the protocol.
Exclusion Criteria:
- Pregnant, breast-feeding, or planning to become pregnant during the study.
- Any investigational medicinal product within 30 days, before Cycle 1 Day 1.
- Part 1 only: more than 4 prior lines of systemic chemotherapy in the advanced or metastatic setting. Part 2 instead applies tumour-type-specific requirements for prior lines of therapy.
- Uncontrolled brain metastases.
- Active or past autoimmune disease or immunodeficiency.
- Idiopathic pulmonary fibrosis, organising pneumonia, drug-induced or idiopathic pneumonia, or evidence of active pneumonia at screening.
- Severe cardiovascular disease within 6 months.
- Significant surgical procedures, other than diagnostic surgery, within 4 weeks before the start of study treatment, or expected to require significant surgery during the study period.
- Known human immunodeficiency virus infection or current active hepatitis B or hepatitis C. Participants with prior HBV infection with negative HBV DNA are eligible. Participants clinically cured of hepatitis C, at least 12 weeks after completing antiviral treatment, are eligible.
- History of life-threatening toxicity related to prior immune therapy, for example an inhibitor of PD-1 or PD-L1, an anti-CTLA-4 agent, or any other drug targeting T-cell activation or immune checkpoint pathways.
- A live virus vaccine within the 4 weeks before Cycle 1 Day 1, or plans to receive a live virus vaccine during the study.
- Corrected QT interval using Fridericia correction greater than 470 milliseconds.
- Prior treatment with DAX-044 or any interleukin-12-based agent.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Part 1 - DAX-044 Monotherapy Dose Escalation
DAX-044 administered at ascending dose levels to participants with advanced solid tumours, to assess safety and tolerability and determine the maximum tolerated dose (MTD). Dose escalation follows a Bayesian optimal interval (BOIN) design. |
DAX-044 monotherapy |
|
실험적: Part 2 - DAX-044 Monotherapy Dose Expansion in Tumour-Specific Cohorts
Part 2 will further evaluate the safety and anti-tumour activity of DAX-044 monotherapy, at dose levels selected from Part 1, in up to 4 tumour-specific expansion cohorts. |
DAX-044 monotherapy |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v6.0
기간: Up to 24 months
|
Up to 24 months
|
|
Maximum Tolerated Dose (MTD) of DAX-044 Based on Dose-Limiting Toxicities (DLTs) (Part 1)
기간: Up to 24 months
|
Up to 24 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Serum Concentrations of DAX-044
기간: Up to 24 months
|
Up to 24 months
|
|
Maximum Observed Serum Concentration (Cmax) of DAX-044
기간: Up to 24 months
|
Up to 24 months
|
|
Time to Maximum Observed Serum Concentration (Tmax) of DAX-044
기간: Up to 24 months
|
Up to 24 months
|
|
Trough Serum Concentration (Ctrough) of DAX-044
기간: Up to 24 months
|
Up to 24 months
|
|
Area Under the Serum Concentration Versus Time Curve Over the Dosing Interval (AUCtau) of DAX-044
기간: Up to 24 months
|
Up to 24 months
|
|
Terminal Half-Life (t1/2) of DAX-044
기간: Up to 24 months
|
Up to 24 months
|
|
Clearance (CL) of DAX-044
기간: Up to 24 months
|
Up to 24 months
|
|
Number of Participants With Anti-Drug Antibodies (ADA) to DAX-044
기간: Up to 24 months
|
Up to 24 months
|
|
Objective Response Rate (ORR) as Assessed by the Investigator per RECIST 1.1
기간: Up to 24 months
|
Up to 24 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- DAX-044-2601
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .